PGEN - PRECIGEN, INC.
IEX Last Trade
0.7408
0.013 1.795%
Share volume: 8,981
Last Updated: Fri 27 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.73
0.01
1.83%
Fundamental analysis
8%
Profitability
0%
Dept financing
9%
Liquidity
54%
Performance
3%
Performance
5 Days
-0.99%
1 Month
-18.77%
3 Months
-21.95%
6 Months
-51.08%
1 Year
-47.24%
2 Year
-41.83%
Key data
Stock price
$0.74
DAY RANGE
$0.69 - $0.75
52 WEEK RANGE
$0.70 - $1.93
52 WEEK CHANGE
-$44.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Helen Sabzevari
Region: US
Website: precigen.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: precigen.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. The company was formerly known as Intrexon Corporation and changed its name to Precigen in January 2020.
Recent news